Related Experiment Videos
Pituitary adenylate cyclase-activating polypeptide inhibits cutaneous immune function
Sreedevi Kodali1, Ilyse Friedman, Wanhong Ding
1Department of Dermatology, Joan and Sanford I. Weill Medical College of Cornell University, New York, NY 10021, USA.
European Journal of Immunology
|October 28, 2003
Summary
Pituitary adenylate cyclase-activating polypeptide (PACAP) suppresses skin immune responses by inhibiting Langerhans cell (LC) antigen presentation and modulating cytokine production. This peptide plays a key role in regulating cutaneous immunity.
Area of Science:
- Immunology
- Dermatology
- Neuroendocrinology
Background:
- Epidermal nerves interact with Langerhans cells (LCs), potentially releasing factors influencing LC function.
- LCs and the LC-like cell line XS106 express mRNA for pituitary adenylate cyclase-activating polypeptide (PACAP) receptors VPAC1 and VPAC2.
Purpose of the Study:
- To investigate the role of PACAP in regulating cutaneous immunity.
- To determine if PACAP affects LC function and antigen presentation.
Main Methods:
- Intradermal PACAP administration before contact sensitizer application in mice.
- Pretreatment of murine epidermal cells and purified LCs with PACAP.
- In vitro assessment of antigen presentation, cytokine secretion (IL-1beta, IL-10), and CD86 expression in LCs and XS106 cells.
Main Results:
- PACAP inhibited the induction of contact hypersensitivity and the elicitation of delayed-type hypersensitivity.
- PACAP suppressed antigen presentation by epidermal cells and purified LCs.
- PACAP inhibited IL-1beta secretion, augmented IL-10 production, and down-regulated CD86 expression in stimulated LCs and XS106 cells.
Conclusions:
- PACAP exerts immunosuppressive effects on cutaneous immunity.
- PACAP's mechanism involves modulating cytokine production and CD86 expression in LCs.